Very proud to share our new paper demonstrating that transformed follicular lymphoma has increased activity of CD40 signalling due to lower levels of miR-29. Evidence that the B-T cell interactions are important in tFL (Filip et al, Leukemia, 2026, rdcu.be/e4HwW).

A fantastic EHA 2026 for the lab: 3 oral presentations, 2 posters, many inspiring discussions, new collaborations taking shape, and, as always, the opportunity to reconnect with friends and colleagues.

Pretty interesting story in @ScienceMagazine this week on what looks like a serious problem in the senescence field. More than 400 papers apparently used the wrong antibody for p16-INK4a — an antibody that actually recognizes a completely different, unrelated protein (a component of the actin cytoskeleton). This affects work on senescent cell accumulation in aging and disease, and most critically, some of the evidence base for senolytic drug research. What concerns me most is that many of these papers somehow got the "right" answer using the wrong antibody. That's not just an innocent reagent mix-up — it raises real questions about data fabrication or selective reporting in at least some of these labs. I've commented before about how ignoring data that doesn't fit the narrative is a major problem in certain areas of the longevity literature (e.g. sirtuins and NAD), and here a potentially widespread example in senescence. Hopefully journals will investigate and retract as necessary, but based on my experience that seems optimistic. One concrete fix is that journals should flag problematic antibody product codes at submission so reviewers can catch this before publication. Reviewers should absolutely be on the lookout for this going forward. However, these fixes won't address the larger problem. We need to understand how these scientists got the results they wanted and published them over 400 times (!!!): whether through intentional deception, incompetence, accident, or some legitimate explanation. Credit for discovering this goes to @addictedtoigno1 who wrote about it first on his blog: For Better Science science.org/content/article/…?

Excited to share the first pre-print from our lab!! Check it out here! biorxiv.org/content/10.64898… We found that many RNA-binding proteins understood to regulate RNA processing can also function like transcription factors and cofactors to directly regulate transcription.

Nivo-AVD now approved in Europe for frontline advanced stage Hodgkin lymphoma based upon @SWOG S1826 trial. lymphomahub.com/medical-info…

Late breaking from #ASCO26 Day 2 for Lymphoma- FrontMIND trial 👉 Tafa Len RCHOP vs RCHOP in 1L DLBCL IPI 3-5 👉 HR for PFS 0.75 👉 2 yr median PFS 72% vs 65% 👉 overall rate G3/4 TEAEs comparable, but increased cytopenias; febrile neutropenia in Tafa/Len/RCHOP ⭐️Potential new SOC option for 1L DLBCL in high risk pts, regardless of COO. My concerns : Difficult regimen with weekly Tafa and 10 days of Len; higher myelosuppression/VTE risk with Len; plus concern of CD19 loss and efficacy of 2L CAR 🚗

Amazing! I’m impressed both with the results for a disease we have struggled against forever: pancreatic cancer; and the fact that we can target what we thought we could not ever: RAS. #ASCO26 @NEJM nejm.org/doi/full/10.1056/NE…

Dr. Daniel Filip (Dano) has completed his PhD. Very proud of him and the work he has done in the lab (Filip et al, Leukemia, 2026 5 other papers). We have a new doctor !

Just out: Majestic Majestec-9 results. #ASCO26 @NEJM Single agent teclistamab beats standard triplet in relapsed myeloma. nejm.org/doi/full/10.1056/NE… @DrOlaLandgren @thanosdimop

Very humbled and honored to receive the Jessenius Award (Physician of the Year 2025) from the Patients Association of the Czech Republic. Named after Jan Jessenius,who performed the first public autopsy in the Czech lands (1600) and wrote an important book on surgical procedures.

38th Olomouc hematology days are coming to its end, ~900 participants from 🇨🇿🇺🇸🇱🇹🇸🇪🇸🇰. Friendship, science and education! Thanks for TOP talks by @MrazLab @GregNowakowski @Dr_Daniel_Molin @prokop_whaaat @Danielakov2 @JamieFlerlage @MarekTrnenyDr team K Polgarova a P Klener! 🤝

Great evening with Greg Nowakowski, thank you for coming to Olomouc Hematology Days !

Moje laborka hledá lab manažera/ku - znalost češtiny je nutná

To follow the @AACR "Holy Week" we are sharing our new paper out today @BCD_AACR : “3D chromosome remodeling in B-cell development and acute lymphoblastic leukemia.” Using integrative chromatin architecture, accessibility, and transcriptional analyses, we show that pediatric B-ALL subtypes harbor distinct 3D genomic states that parallel developmental arrest and support subtype-specific oncogenic programs. We further identify ERG as a key regulator in ETV6::RUNX1 B-ALL, with implications for leukemic maintenance and differentiation blockade. Finally, we map 3D changes in healthy human B cell development drawing parallels to specific disease states. aacrjournals.org/bloodcancer…

I don’t know if you saw the MASSIVE news announced by @ERC_Research today: from now on,if you get a B at step 1 you are eligible to apply at N 3(!!!) years. Say you got a B in STG2026 step 1, you thought you could apply in STG2028, but no: only in STG2029! erc.europa.eu/news-events/ne…

Hopefully first submissions before September (that’s what is currently shown in the forecast).

We're in this week's Nature! We propose a model of how a cell learns by running an evolutionary algorithm: exploring different gene-regulatory combinations and using feedback responses to stabilize those combinations that reduce stress levels. Full text: nature.com/articles/s41586-0…

Z akademicekého sněmu AV: problémem české vědy není neefektivní distribuce prostředků, ale především to, že těch prostředků je málo